Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic, Dana-Farber Expand ICE COLD-PCR License

NEW YORK (GenomeWeb) — Transgenomic said today that it has signed a licensing deal with the Dana-Farber Cancer Institute for exclusive worldwide rights to develop and commercialize multiplexed versions of its ICE COLD-PCR technology.

The new license covers all fields and applications of the multiplexed technology, enabling the simultaneous detection of multiple DNA mutations from a single liquid sample such as blood or urine, Transgenomic said.

The deal also expands on an existing license between Transgenomic and Dana-Farber for ICE COLD-PCR, which stands for "improved and complete enrichment-coamplification at lower denaturation temperature PCR" and was developed in the laboratory of Dana-Farber researcher Mike Makrigiorgos.

In 2009, Omaha, Neb.-based Transgenomic signed an exclusive licensing agreement with Dana-Farber to use COLD-PCR combined with Sanger sequencing and for mitochondrial DNA analysis. They followed that agreement in 2011 with an expanded license to include ICE COLD-PCR and the analysis of COLD-PCR products by pyrosequencing.

ICE COLD-PCR selectively focuses on only the mutated DNA in tumors that is useful for cancer diagnosis, monitoring, and treatment. It detects mutated DNA at 100- to 400-fold greater sensitivity than conventional approaches and enables identification of all tumor mutations, known and unknown, the company said.

"Multiplexing makes our ICE COLD-PCR technology far more efficient and allows us to assemble targeted panels of relevant mutations that can be simultaneously analyzed from a single sample," Transgenomic CEO Paul Kinnon said in a statement. "This should greatly increase its availability for routine use in cancer therapy, as well as for our biopharmaceutical customers who plan to use [multiplexed] ICE COLD-PCR to develop new cancer treatments and companion diagnostics."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.